Connect with us

Technology

111, Inc. Announces Change to Board of Directors

Published

on

SHANGHAI, Nov. 4, 2024 /PRNewswire/ — 111, Inc. (“111” or the “Company”) (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that Dr. Leon Lian Yong Chen has tendered his resignation from the position as the Company’s director for personal reasons, effective on November 4, 2024. The board has also appointed Mr. Yang “Luke” Chen, currently serving as the Company’s Senior Finance Executive, as a new director, effective November 4, 2024.

Dr. Lian Yong Chen has served on the board of directors of the Company since May 2019. “I am grateful to Dr. Chen for his significant contributions during his term of office. His knowledge and advice have been invaluable in propelling our goals and strategies for long-term achievements. On behalf of the board, I extend best wishes to Dr. Chen and look forward to further collaborating with him in the future,” said Mr. Gang Yu, Co-Founder and Executive Chairman of the Company.

Regarding the appointment of Mr. Yang “Luke” Chen, Mr. Gang Yu added, “We are delighted to welcome Luke to our board of directors. His extensive financial expertise and deep understanding of our business will be instrumental as we continue to drive our strategic initiatives forward. I am confident that his leadership and insights will contribute to our ongoing success and growth.”

Forward-Looking Statements

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,”” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company’s ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company’s ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq’s continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

About 111, Inc.

111, Inc. (NASDAQ: YI) (“111” or the “Company”) is a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company’s online platform, 1 Medicine, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring.

For more information on 111, please visit: http://ir.111.com.cn/

 

View original content:https://www.prnewswire.com/news-releases/111-inc-announces-change-to-board-of-directors-302294966.html

SOURCE 111, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Siyata Mobile Products Deployed by EMS Organization in Papua New Guinea

Published

on

By

VANCOUVER, BC, Nov. 13, 2024 /CNW/ — Siyata Mobile Inc. (Nasdaq: SYTA) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (“PoC”) devices and cellular signal booster systems, today discussed the deployment of its SD7 handsets and VK7 vehicle kits by The National St John Ambulance Service (NStJA), a trusted life-saving service in Papua New Guinea, the most populous Pacific island country.

Marc Seelenfreund, CEO of Siyata, commented, “By upgrading from standard smartphones to our ruggedized SD7 handsets and VK7 vehicle kits, NStJA is experiencing the many benefits of our solution. Our devices stand up to the demanding environments faced by first responders and medical personnel. Integrated with the Zello Push-to-Talk app, our solution for this customer is providing secure and reliable communication that far exceeds the performance of standard smartphones. Our global deployments continue to increase, and we are pleased that our reach now extends to Papua New Guinea, and we are also encouraged by the number of new customers who are selecting Zello as their preferred PTT application.” 

Mark Cannon, Chief Executive for NStJA, commented, “We provide mission-critical evacuation and medical services to residents and visitors of our country. It is absolutely critical that we have a communications solution that is reliable and effective. Since upgrading from standard smartphones and a traditional UHF radio system, our team is finding the Siyata devices to be simpler to use with a PTT button, provide loud and clear audio and have a better battery life. We are quite pleased with Siyata’s solution.”

About Siyata Mobile

Siyata Mobile Inc. is a B2B global developer and vendor of next-generation Push-To-Talk over Cellular handsets and accessories. Its portfolio of rugged PTT handsets and accessories enables first responders and enterprise workers to instantly communicate over a nationwide cellular network of choice, to increase situational awareness and save lives. Police, fire, and ambulance organizations as well as schools, utilities, security companies, hospitals, waste management companies, resorts and many other organizations use Siyata PTT handsets and accessories today.

In support of our Push-to-Talk handsets and accessories, Siyata also offers enterprise-grade In-Vehicle solutions and Cellular Booster systems enabling our customers to communicate effectively when they are in their vehicles, and even in areas where the cellular signal is weak.

Siyata sells its portfolio through leading North American cellular carriers, and through international cellular carriers and distributors.

Siyata’s common shares trade on the Nasdaq under the symbol “SYTA”, and its warrants trade under the symbol “SYTAW”.

Visit www.siyata.net and unidencellular.com to learn more.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Siyata’s current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of Siyata could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Siyata’s filings with the Securities and Exchange Commission (“SEC”), and in any subsequent filings with the SEC. Except as otherwise required by law, Siyata undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites and social media have been provided as a convenience, and the information contained on such websites or social media is not incorporated by reference into this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/siyata-mobile-products-deployed-by-ems-organization-in-papua-new-guinea-302303831.html

SOURCE Siyata Mobile Inc.

Continue Reading

Technology

Forsea Achieves Record-Breaking Cell Density for Its Cultivated Seafood

Published

on

By

Forsea’s technology sets new industry standard, paving the way for affordable cultivated seafood production.

REHOVOT, Israel, Nov. 13, 2024 /PRNewswire/ — Cell-cultivated seafood innovator Forsea struck a major breakthrough in making freshwater eel farming a viable commercial reality. The start-up announced its organoid technology reached a record-breaking cell density of more than 300 million cells/ml, and with minimal and precise use of cultured media ingredients.

This is the highest cell density recorded in the field, moving Forsea to the forefront of cultured seafood production efficiency. The landmark technology allows for a scalable and highly cost-effective supply for the hugely popular traditional Japanese delicacy, eel (unagi) whose availability has been significantly hampered by overfishing and the destruction of aquatic ecosystems.

Eel is Big in Japan

Forsea is currently focusing on manufacturing cultured freshwater eel due to the immense market potential, particularly in Japan. As the world’s largest consumer of eel, Japan recorded sales of 140,000 tons in 2023—50% of total global sales. The traditional Japanese dish unagi (eel) is considered a premium delicacy, prized not only for its rich flavor and tender texture but also because of its rarity. Freshwater eel is endangered and cannot be commercially bred in captivity. Demand for eel far surpasses the industry’s current supply capabilities, translating to skyrocketing prices.

Better, faster, and economical

Setting a new standard for “blue ocean” initiatives, Forsea created a new approach to cell cultivating fish tissues outside of their native water habitats via organoid technology. Forsea’s patent-protected platform involves creating the ideal environment for animal cells to spontaneously assemble into three-dimensional tissue structures with their natural composition of fat, muscle and connective tissue.

This method not only echoes the natural growth process of these tissues in a living animal, giving it a closer-to-nature edge, it bypasses the scaffolding stage and is dramatically less dependent on expensive growth factors. This makes the process highly affordable and positions its cell-grown version to price parity (or potentially lower)  with traditional aquafarmed eel, a key challenge the cell-based industry was desperate to overcome.

Ample affordable cultivated eel not oceans away

“The breakthrough to this level of cell density highlights the strength of our organoid technology,” exclaims Moria Shimoni, CTO of Forsea. “It’s a validation of our approach to high-efficiency cultivation of seafood to meet both economic and sustainability goals at scale”.

After completing its proof-of-concept continuous harvesting process, Forsea reports it is ready to take production of its cultured fish products to the next phase of commercial scale-up.

“Forsea’s organoid technology requires less capital expenditure than other technologies,” explains Roee Nir, Founder and CEO of Forsea. “Achieving this level of cell density with minimal resources will translate to substantial reductions in the unit of economics and will bring cultured seafood production to a cost that is actually below the traditional market price. This is major milestone for Forsea and validates our vision of making sustainable, high-quality seafood affordable and widely accessible. It also sets a powerful precedent for scaling other cultured seafood products and establishing sustainable alternative supply chains for ecologically sensitive species.”

Forsea’s cell-cultured eel is expected to ease the strain on the world’s eel populations and reduce environmental impact of traditional eel farming. This encompasses reducing global warming potential, water consumption, and land use and alleviated pressure on marine ecosystems by focusing on endangered species.

“Our recent industry survey shows that cultivated meat production is definitely not a one-size-fits-all approach,” says Elliot Swartz, Principal Scientist Cultivated Meat, GFI. “It’s encouraging to see positive data from companies showing how different methods can address challenges in cost and scale. I’m especially pleased to see a GFI research grantee, Dr. Iftach Nachman, help a startup pioneer new ways of cultivating meat. This is a great example of how foundational open-access science enables and makes possible follow-on work by the private sector.”   

The company is preparing for commercial launch of its unagi product in 2026. Earlier this year, Forsea held a successful tasing event at the reputable ‘a’ restaurant in Tel Aviv, where it served the world’s first cultivated unagi kabayaki—grilled fresh eel on a bed of aromatic rice—receiving rave reviews. Among the tasters where representatives from the Japanese embassy and various Japanese food companies based in Israel.

About Forsea
Forsea was founded by biotech engineer Roee Nir, MBA; Moria Shimoni, PhD; Iftach Nachman, PhD; and Yaniv Elkouby, PhD with support from the Israeli Innovation Authority (IIA) and The Kitchen Hub. It has garnered seed backing from Target Global, PeakBridge VC, Future Food Fund, Zora Ventures, FoodHack, and M&H Ventures. Forsea’s organoid approach to cultivating fish tissue involves creating an ideal environment for fish cells to spontaneously form their natural composition of native fat and muscle. They grow as a three-dimensional tissue structure, just as in nature.

For more information, contact:

Company Contact

Forsea Foods Ltd.

Roee Nir, CEO and Co-Founder

Email: info@forseafoods.com

Web:   www.forseafoods.com 

Press Contact

NutriPR

Liat Simha

Tel: +972-9-9742893

E-mail: liat@nutripr.com

Web: www.nutripr.com

 

Photo: https://mma.prnewswire.com/media/2555423/Forsea_Foods.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/forsea-achieves-record-breaking-cell-density-for-its-cultivated-seafood-302304008.html

SOURCE Forsea Foods

Continue Reading

Technology

EP3® Technology Powers $560 Million in U.S. Election Contracts: The Invisible Engine Behind ForecastEx’s Fast-Growing Predictions Market

Published

on

By

AUSTIN, Texas, Nov. 13, 2024 /PRNewswire/ — ForecastEx, a wholly-owned subsidiary of Interactive Brokers (IBKR) and a US-regulated predictions exchange and clearinghouse, processed an impressive $560 million+ in election contracts for the 2024 U.S. general election. The innovative technology driving those contracts? Connamara Technologies’ EP3 ® matching engine and exchange platform.

The election showed EP3’s resilience and commitment to seamless, high-volume processing for predictive events.

In the days leading up to – and during – election night, EP3 operated like the gears of a fine timepiece: inconspicuous, vital, and unfaltering. This synchronicity of unyielding performance weathered waves of volatility and seamlessly processed trades at a record volume.

Working in concert with ForecastEx’s internal teams, Connamara Technologies’ engineers monitored systems around the clock, ready to respond to surges in trade volume with precision and expertise. The team’s commitment went beyond standard duty, ensuring unparalleled service during this first-in-a-lifetime historic trading event.

With EP3 powering its trading, ForecastEx has not only established a benchmark for transparency in elections but has also offered the public real-time, market-based insights into election sentiment. EP3 operates from a legacy of trading knowledge that dates back to the late 1980s.

“While you may not recognize the name EP3 just yet, you’ll certainly recognize our impact. Whether you placed a trade or watched from afar, the 2024 election proved our technology’s resilience and our team’s commitment to deliver seamless, high-volume processing at every turn for future predictive events,” said Jim Downs, Co-Founder and CEO of Connamara Technologies.

As predictions markets continue to grow, the unseen elements – the EP3 technology and the engineers who support it – will remain crucial to providing reliable, transparent platforms that allow for public sentiment to be expressed and analyzed in real-time. Moving forward, Connamara Technologies aims to expand EP3’s reach, enabling new exchanges and markets to take advantage of this dependable backbone technology.

About Connamara Technologies

Connamara Technologies is the leading provider of fully-integrated exchange infrastructure, empowering new and existing exchanges to operate with exceptional efficiency and reliability. Its EP3 platform is a new breed of exchange and clearing technology that seamlessly integrates all key functions into a single, robust platform. It is cost-accessible, adaptable, scalable and quick-to-market. Engineered for the evolving needs of the next generation of exchanges and marketplaces, EP3 is shaping the future of financial markets.

For more, visit www.connamara.tech or LinkedIn.

Media Contact:

Claire Downs
marketing@connamara.tech

View original content:https://www.prnewswire.com/news-releases/ep3-technology-powers-560-million-in-us-election-contracts-the-invisible-engine-behind-forecastexs-fast-growing-predictions-market-302303513.html

SOURCE Connamara Technologies

Continue Reading

Trending